Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies.
The CNS-IPI was derived from a population of patients (n=2164) enrolled in the German clinical trials and subsequently validated in a population of 1597 patients treated in British Columbia, Canada. The score is based on the original IPI factors with the addition of kidney and/or adrenal involvement. The final score is able to differentiate patients into 3 distinct prognostic groups for CNS recurrence/progression.
References
Schmitz et al.
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
JCO 2016 (DOI: 10.1200/JCO.2015.65.6520)
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email contact@qxmd.com